Indication
Treatment in adults of other chronic fibrosing interstitial lung diseases with a progressive phenotype.
Medicine details
- Medicine name:
- nintedanib (Ofev)
- SMC ID:
- SMC2331
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Full
- Publication due date:
- Q2 2021
- SMC meeting date:
- Q2 2021
- Patient group submission deadline:
- 01 March 2021